Table 1 |
|||||
|
Antibodies and Interpretation Criteria |
|||||
|
Antibody |
Source |
Clone |
Dilution |
Positive Control |
Positive Result |
|
|
|||||
|
PSA |
Dako |
Polyclonal |
1:10,000 |
Prostate |
Any cytoplasmic staining |
|
|
|||||
|
PSAP |
Dako |
PASE/4LJ |
1:1,280 |
Prostate |
Any cytoplasmic staining |
|
|
|||||
|
AR |
Dako |
F39.4.1 |
1:40 |
Prostate |
Nuclear staining ≥ 10% |
|
|
|||||
|
ER |
Dako |
ID5 |
1:50 |
Breast carcinoma |
Nuclear staining ≥ 10% |
|
|
|||||
|
PR |
Dako |
PgR636 |
1:400 |
Breast carcinoma |
Nuclear staining ≥ 10% |
|
|
|||||
|
PSA - prostate specific antigen; PSAP - prostate specific acid phosphatase; AR - androgen receptor; ER - estrogen receptor; PR - progesterone receptor. |
|||||
|
Kraus et al. Diagnostic Pathology 2010 5:63 doi:10.1186/1746-1596-5-63 |
|||||
